(Q42978232)

12 November 2017

title

Sustained viral load reduction in treatment-naive HCV genotype 1 infected patients after therapeutic peptide vaccination (English)

1 reference

12 November 2017

1 reference

5

Michael P Manns

1 reference

12 November 2017

Christoph S Klade

1

1 reference

12 November 2017

Elisabeth Schuller

series ordinal

2

1 reference

12 November 2017

Thomas Boehm

series ordinal

3

1 reference

12 November 2017

Alexander von Gabain

series ordinal

4

1 reference

12 November 2017

language of work or name

English

0 references

publication date

6 March 2012

1 reference

12 November 2017

1 reference

12 November 2017

volume

30

1 reference

12 November 2017

issue

19

1 reference

12 November 2017

page(s)

2943-2950

1 reference

Epidemiology of hepatitis C: geographic differences and temporal trends

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

Global epidemiology of hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

Correlation between virus genotype and chronicity rate in acute hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

Hepatitis C virus: molecular biology and genetic variability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

The hepatitis C virus: overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

CD8 T cell dysfunction during chronic viral infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

Maternal Neutralizing Antibody and Transmission of Hepatitis C Virus to Infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

Development of hepatitis C virus vaccines: challenges and progress.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

Hepatitis C vaccine: supply and demand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

Rapid effector function in CD8+ memory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

A step forward in therapy for hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.070

10.1016/J.VACCINE.2012.02.070

7 January 2021

Identifiers

DOI

1 reference

12 November 2017

1 reference